The funds were awarded after Prometheus developed and commercialized its second program, PR600, a precision antibody for the treatment of patients with inflammatory bowel disease.
The Dr. Falk Pharma partnership allowed Prometheus to “accelerate the PR600 program by sharing costs, resources and drug development know-how, which has resulted in the achievement of this important milestone within the first year of our collaboration,” Prometheus President and CEO Mark McKenna,said in a June 21 news release.
Prometheus said it plans to file an investigational new drug application in the third quarter and explore PR600’s use in indications beyond IBD.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.